

# ADEQUACY OF SOTROVIMAB PRESCRIPTION IN SARSCOV-2 INFECTION IN A UNIVERSITY HOSPITAL

5PSQ-099

T. BLANCO ESPESO<sup>1</sup>, M. FLORIDO FRANCISCO<sup>1</sup>, R. SERRANO GIMÉNEZ<sup>1</sup>, M. RODRIGUEZ JORGE<sup>1</sup>.  
<sup>1</sup>HOSPITAL JUAN RAMÓN JIMÉNEZ, HOSPITAL PHARMACY, HUELVA, SPAIN

J06-IMMUNE SERA AND IMMUNOGLOBULINS

## BACKGROUND AND IMPORTANCE


The Spanish Medicines and Health Products Agency (AEMPS) has developed criteria to adapt the prescription of sotrovimab<sup>1</sup>, due to the pandemic situation and the limited drug stock.

## AIM AND OBJECTIVES

To describe the patients' population on treatment with sotrovimab and to assess the adequacy of this prescription according to the criteria established by the AEMPS.


## METHODS AND MATERIALS

Retrospective observational study analysing all sotrovimab prescriptions in patients with SARS-CoV-2 infection from 01/25/2022 to 08/31/2022.



Prescriptions for sotrovimab were collected and analysed to determine whether they met the criteria and whether they were accepted. Data collected from electronic medical records and processed using Excel2019®.

## RESULTS



Ten per cent of the applications did not meet the criteria: four of them were not accepted (patients did not belong to any risk group); one was accepted, although it was a well-controlled HIV.

## CONCLUSIONS AND RELEVANCE

The main profile of patients treated with sotrovimab is men with solid organ transplantation, vaccinated and with negative immunity to SARS-CoV-2. Although the appropriateness of the prescription is high, it is necessary to continue protocolising the use of this drug to ensure its rational use.

## REFERENCES AND/OR ACKNOWLEDGEMENTS

1. <https://www.aemps.gob.es/medicamentos-de-uso-humano/acceso-a-medicamentos-en-situaciones-especiales/criterios-para-valorar-la-administracion-de-las-nuevas-alternativas-terapeuticas-antivirales-frente-a-la-infeccion-por-sars-cov-2/>

